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Introduction
Proton pump inhibitors (PPIs) are the most effective agents available for reducing acid secretion; they irreversibly in-
hibit the hydrogen potassium ATPase in the gastric parietal 
cells and thus can reduce acid secretion to negligible amounts.1 
Since the late 1980s, these medications have been used to treat 
various acid-related disorders such as peptic ulcer disease, eradi-
cation of Helicobacter pylori (H. pylori), treatment and preven-
tion of gastroduodenal ulcers associated with non-steroidal anti-
LQÀDPPDWRU\GUXJV16$,'V=ROOLQJHU(OOLVRQV\QGURPHDQG
PDQDJHPHQWRIJDVWURHVRSKDJHDOUHÀX[GLVHDVH*(5'2–11
PPIs are used extensively, over long periods of time as treat-
ment for GERD and in the much less common Zollinger-Ellison 
syndrome. GERD is prevalent; up to one-third of adults suffer 
from this disease.12 Considering the propensity for esophagitis to 
relapse, in this large group of patients maintenance acid suppres-
sive therapy is often necessary. Therefore drug safety becomes an 
important issue.7,12
The main concern regarding maintenance therapy of PPIs has 
been the propensity of PPI-treated patients to develop chronic 
atrophic gastritis.13–15 Although the risk of atrophic gastritis in this 
context remains unclear, it could theoretically lead to an increased 
incidence of gastric cancer.16 H. pylori infection might be a po-
tential risk factor for developing atrophic gastritis in long-term 
PPI users.14 One trial demonstrated that H. pylori-positive patients 
with GERD who had been treated with omeprazole were at in-
creased risk of developing atrophic gastritis.13 Recent studies sug-
gest that eradication of H. pylori infection prior to long-term acid 
suppression with PPI may prevent the development of atrophic 
gastritis.17,18
Another major safety concern with omeprazole is the induction 
of hypergastrinemia which can occur with both short and long-
term omeprazole therapy and may be more severe in patients with 
H. pylori infection.19,20 Long-term studies of omeprazole in pa-
tients with Zollinger-Ellison syndrome have found no increase in 
fasting serum gastrin concentrations and no evidence of gastric 
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carcinoid tumors. In some studies carcinoid tumors of the gastric 
mucosa have been associated with long-term PPI use in rats.21–23 
However, it remains to be determined if prolonged use of PPIs can 
induce carcinoid tumors in humans.
By taking this into consideration, we have conducted a system-
atic review to address the question of long-term PPI safety and 
its relation to the development of premalignant and malignant le-
sions in the stomach.
Materials and Methods
This was a computerized literature search conducted in MED-
LINE (1950 to 2013, Feb. week 4), and Cochrane Library (up to 
Issue 1 of 12, January 2013) that included The Cochrane Database 
of Systemic Reviews (CDSR), The Cochrane Central Register of 
Controlled Trials (CENTRAL) and  Database of Abstracts of Re-
view of Effectiveness (DARE). Table 1 shows the search strategy 
for each database. We limited our search to studies in humans. 
There were no language restrictions for either searching or trial 
inclusion.
We hand-searched the abstracts from 1995 to 2012 from the 
American Digestive Disease Week (DDW) published in Gas-
troenterology and the United European Gastroenterology Week 
(UEGW) published in Gut. 
We scanned reference lists of retrieved articles to identify further 
relevant trials.
Authors of trials published only as abstracts were requested to 
contribute full data sets or completed papers. 
All randomized controlled trials (RCTs) that compared PPIs 
YHUVXVSODFHERDQWLUHÀX[$56VXUJHU\RUQRWUHDWPHQWDQGDG-
dressed the main outcomes (see below) were eligible for inclusion 
in this review. 
Included were adults without any premalignant/malignant le-
sions at baseline maintained on any type of PPI for six months 
or more. The control group included one of the following sub-
set of patients: i) patients who underwent ARS; ii) patients who 
XQGHUZHQW HQGRVFRSLF DQWLUHÀX[ WUHDWPHQW DQG LLL WKRVHZKR
received one of the following: no treatment, placebo, H2 blockers, 
or antacids.
The experimental intervention was PPI use for six months or 
more. Included were any studies that had at least one intervention 
arm and one valid control arm.
Only oral therapies were considered regardless of dose. We ana-
lyzed all the included studies of long-term PPI versus any control, 
together, as one intervention group.
The primary outcome of this review was to compare the inci-
dence of (pre)malignant gastric lesions (atrophic gastritis, carci-
noid tumor, intestinal metaplasia and dysplasia, gastric adenoma 
and dysplasia and any type of gastric malignancy) in patients who 
received long-term (>6 months) PPI with those who did not.
We screened the titles and abstracts of all potential relevant stud-
ies before retrieval of full articles. In cases where the titles and 
abstracts were ambiguous the full articles were assessed for rele-
vance. Relevant trials were determined by consensus between the 
reviewers. Two reviewers (LE and SNM) independently applied 
the selection criteria according to the pre-stated eligibility criteria; 
disagreements were resolved by consensus.
Two reviewers (LE and SNM) independently extracted data. 
Discrepancies in the interpretation were resolved by consensus.
Assessment of study quality 
The authors followed the instructions given in The Cochrane 
Handbook for Systematic Reviews of Interventions for the assess-
ment of the quality of each study, which was primarily based on 
WKH¿YHFRPSRQHQWVRILJHQHUDWLRQRIDOORFDWLRQVHTXHQFHLL
allocation concealment, iii) blinding, iv) incomplete outcome data 
reporting, and v) selective outcome reporting.
Quality assessments of the studies were performed independent-
ly by two reviewers (LE and SNM) and discrepancies in interpre-
tation were resolved by consensus. We did not exclude studies on 
the basis of a low quality score.25
We performed statistical analysis using Review Manager 5.1 
(RevMan) software. Pooled P values of all studies were calcu-
lated based on the Mantel-Haenszel method. Relative risk (RR) 
Table 1. Strategy of electronic searches.
Cochranez1 Omeprazole /explode all trees (MeSH)
z2 Proton Pump Inhibitors
z3 Lanzoprazole or Pantaprazole or Rabeprazole or Esomeprazole or Omeprazole
z4 (z1 or z 2 or z 3)
z5 Gastritis, Atrophic / explode all trees (MeSH)
z6 Stomach Neoplasms /explode all trees (MeSH)
z7 Metaplasia/ explode all trees (MeSH)
z8 Carcinoid tumor/ explode all trees (MeSH)
z9 (z5 or z6 or z7 or z8)
z10 (z4 AND z9)
Medline in Entrez PubMed
z1 “Proton Pump Inhibitors”
z2 Omeprazole (MeSH) / all Sub Heading
 z3 (Omeprazole or Lanzoprazole or Rabeprazole or Pantaprazole or Esomeprazole)
z4 (z1 or z2 or z3)
 z5 “Stomach Neoplasms” (MeSH) / all Sub Heading
z6 “Gastritis, Atrophic” (MeSH) / all Sub Heading
z7 Metaplasia (MeSH) / all Sub Heading
z8 “Carcinoid tumor”(MeSH) / all Sub Heading
z9 (z5 or z6 or z7 or z8)
z10 (z4 and z9)
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ZLWKFRQ¿GHQFHLQWHUYDOVZDVWKHHIIHFWPHDVXUHRIFKRLFH
for dichotomous data for all effect sizes. Simple parallel RCTs 
were included in the meta-analyses.
All analyses of outcomes were based on intention-to-treat prin-
ciple. In this case, we included data on the total number of ran-
domized participants, irrespective of how the original trials ana-
lyzed the data. This involved imputing outcomes for the missing 
patients.
When possible we performed a meta-analysis. At this case tests 
for heterogeneity were used. When there was high level of hetero-
geneity, we calculated RR by the random-effects model in addi-
WLRQWRWKH¿[HGHIIHFWPRGHO
7KHHIIHFWRILQWHUYHQWLRQZDVFRPSXWHGE\WKH¿[HGHIIHFWRU
random-effects model depending on the results of our heterogene-
ity test.
We performed the following subgroup analyses:
1. Studies where patients were treated for one year or less and 
those where patients were treated over one year;
2. Studies where the dose of PPI was equal to 20 mg omepra-
zole or less and those where the dose of PPI was over 20 mg.
We categorized the included studies into three groups of low, 
moderate and high risk of bias. Subsequently we performed a 
sensitivity analysis by only including studies that had low risk 
of bias.
Results
Results of the search  
Our electronic search resulted in 8227 citations. After exclusion 
of repetitive records, 93 records that included clinical trials, ob-
servational studies, reviews, letters and editorials were considered 
to be relevant upon initial screening and three studies (Lundell 
1999, Lundell 2006, Genta 2003)14,25,36 met the inclusion criteria. 
We reviewed full-texts and references from all 93 relevant papers. 
In addition, seven studies (Dent 1994, Hallerback 1994, Gouch 
1996, Johnson 2001, Vakil 2001, Meining 1998, Nishi 2005) 26–32 
that met the inclusion criteria were retrieved from the references 
of these papers. The information in one paper (Nishi 2005)32 was 
LQVXI¿FLHQWIRULQFOXVLRQLQWKHPHWDDQDO\VLVDQGRXUHIIRUWVWR
obtain additional information from the authors were unsuccessful, 
WKXVWKHWULDOZDVH[FOXGHG:HLGHQWL¿HGWKUHHRWKHUUHOHYDQWSD-
pers (Gardner 1999, Lee 1996, Richter 2003) 33–35 through hand-
searching. Only the abstracts of these three papers were pub-
lished; their full-texts were not available even after contacting the 
authors. Therefore, these three were not included in the review.
Included studies  
Since the constructive, helpful data of two included studies 
(Johnson 2001, Vakil 2001)29,30 were published in another review 
(Genta 2003)36 we used this review for the purpose of data extrac-
tion. The full texts of all included studies were precisely evaluated 
and relevant data extracted. Table 2 fully explains the characteris-
tics of the included studies.
Totally, we included six RCTs (Dent 1994; Hallerback 1994; 
Lundell 1999; Gouch 1996; Johnson 2001; Vakil 2001) 14, 26–30 in 
the pooled analysis. Each included one or more comparisons as 
described below. 
PPI maintenance versus placebo 
Two multicenter RCTs (Johnson 2001; Vakil 2001) with a total 
of 693 participants compared esomeprazole (10, 20, and 40 mg/
day) to placebo. 20, 30
7KHVHWULDOVVHSDUDWHO\DVVHVVHGFKURQLFLQÀDPPDWLRQLQWHVWLQDO
metaplasia, and atrophy in the antrum and/or corpus mucosa.
33,PDLQWHQDQFHYHUVXVDQWLUHÀX[VXUJHU\$56
One RCT (Lundell 1999) of 310 participants compared omepra-
zole (20, and 40 mg/day) with ARS.14 This study assessed for 
FKURQLF LQÀDPPDWLRQ LQWHVWLQDOPHWDSODVLD DQG DWURSK\RI WKH
corpus, in addition to simple (diffuse) hyperplasia, linear hyper-
plasia, and micronodular hyperplasia of the ECL cells. This was 
the only trial which separately evaluated H. pylori-negative and 
positive patients.
PPI versus ranitidine maintenance 
Two RCTs (Dent 1994; Hallerback 1994) with a total of 551 
participants compared omeprazole (20 mg/day) to ranitidine (150 
mg twice daily). They both evaluated simple (diffuse) and linear 
hyperplasia of the ECL cells. 26,27
One RCT (Gouch 1996) compared lansoprazole (30 and 15 mg/
day) to ranitidine (300 mg twice daily). In this study, 266 partici-
SDQWVZHUHDVVHVVHGIRUFRUSRUDODQGDQWUDOFKURQLFLQÀDPPDWLRQ
as well as simple (diffuse), linear, and micronodular hyperplasia 
of the ECL cells following treatment. 28
([FOXGHGVWXGLHV
After careful inspection of the included studies, we excluded 
two papers. One (Lundell 2006) 26 was an extension of a previ-
RXVO\LQFOXGHGVWXG\WKDWKDGDVLJQL¿FDQWQXPEHURISDWLHQWVORVW
to follow-up. The other (Meining 1998) 31 was a multicenter, RCT 
ZKLFKODFNHGVXI¿FLHQWGDWDWREHLQFOXGHGLQWKH¿QDODQDO\VLV
Appendix 1 lists the characteristics and reason(s) for exclusion of 
other studies.
Risk of bias in included studies  
Four of the included RCTs (Lundell 1999; Dent 1994; Haller-
back1994; Gough 1996)14,26–28 had moderate risk of bias, whereas 
two (Johnson 2001; Vakil 2001)29,30 had low risk of bias according 
to previously described criteria. Table 3 explains how the quality 
of each study was assessed.
Study  Generation of allocationsequence
 Allocation
concealment Blinding Follow-up Risk of bias
Dent 199426 Adequate Unclear Adequate Adequate Moderate
Gough 199628 Unclear Unclear Adequate Adequate Moderate
Hallerback 199427 Unclear Unclear Adequate Partially described Moderate
Johnson 200129 Adequate Adequate Adequate Adequate Low
Vakil 200130 Adequate Adequate Adequate Adequate Low
Lundell 199914 Adequate Unclear Adequate Unclear Moderate
Table 3.5LVNRIELDVLQLQFOXGHGVWXGLHV
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Effect of interventions  
PPI maintenance versus control
&KURQLF FRUSXV LQÀDPPDWLRQ $QDO\VLV  ZDV VWXGLHG LQ
four RCTs (Lundell 1999; Gough 1996;  Johnson 2001; Vakil 
2001).14,28–30 It was scored both at baseline and at the end of the 
study. Overall, 30 out of 736 patients on PPI maintenance therapy 
VFRUHGZRUVHRQWKHLU¿QDOELRSVLHVFRPSDUHGWRRXWRISD-
tients in the control group (RR = 1.30, CI: 0.68 to 2.48, P = 0.43).
Three RCTs (Lundell 1999; Johnson 2001; Vakil 2001)14,29,30 
evaluated corporal atrophy, corporal intestinal metaplasia and 
FKURQLF DQWUDO LQÀDPPDWLRQ$JDLQ WKH VFRUHV IRU FRUSRUDO DW-
rophy and intestinal metaplasia were compared at baseline and 
study completion. The majority of patients on PPI had either a de-
crease or no change in their scores. The numbers of patients with 
increased corporal atrophy or intestinal metaplasia scores were 
not statistically different between the PPI maintenance group (P 
= 0.92) and controls (P = 0.85). Similar results were found when 
FKURQLFDQWUDOLQÀDPPDWLRQVFRUHVZHUHFRPSDUHGP = 0.16). 
Simple (diffuse), linear and micronodular ECL hyperplasia 
were reported in six RCTs (Lundell 1999; Johnson 2001; Vakil 
2001; Hallerback 1994; Gough 1996; Dent 1994).14,26–30 With the 
exception of one RCT (Hallerback 1994)27 where micronodular 
and linear hyperplasia were reported together as a single out-
come (i.e., focal hyperplasia), simple, linear and micronodular 
ECL hyperplasia were separately investigated. We considered fo-
cal and linear hyperplasia as a single entity while performing the 
meta-analysis. Patients in the PPI maintenance group mostly had 
normal ECL scores at baseline. Of 1079 patients on PPI therapy, 
only 23 developed simple (diffuse) hyperplasia and 13 developed 
linear hyperplasia. Among the 514 controls, 1 developed simple 
(diffuse) hyperplasia and 3 developed linear hyperplasia. These 
GLIIHUHQFHVZHUHQRWVWDWLVWLFDOO\VLJQL¿FDQWP = 0.71 for simple 
hyperplasia and P = 0.35 for linear hyperplasia). Despite the fact 
that no patients in the control group developed micronodular hy-
perplasia, no demonstrable difference in its incidence could be 
found between the PPI maintenance group and controls (RR = 
3.62, CI: 0.71 to 18.35).
PPI versus control based on duration of PPI use
Subgroup analysis was performed based on duration of PPI use 
(i.e., less than or equal to 12 months compared to more than 12 
months). Longer duration of PPI maintenance therapy was not as-
VRFLDWHGZLWKDZRUVHRXWFRPHZKHQFKURQLFFRUSRUDOLQÀDPPD-
tion, atrophy and intestinal metaplasia were evaluated. This also 
held true for simple (diffuse), linear and micronodular (ECL) hy-
perplasia.
PPI versus control based on PPI dose
Subgroup analysis compared low (less than 20 mg/day) and high 
(equal or more than 20 mg/day) dose PPI regimens.  There were 
no differences between treatment regimens for chronic corporal 
LQÀDPPDWLRQ VLPSOH GLIIXVH K\SHUSODVLD OLQHDU K\SHUSODVLD
and micronodular hyperplasia of the ECL cells.
33,YHUVXVFRQWUROEDVHGRQ+HOLFREDFWHUS\ORUL+S\ORULVWDWXV
Only one RCT (Lundell 1999)14 compared PPI (i.e., omeprazole) 
maintenance therapy with controls (i.e., ARS). The number of pa-
WLHQWVZLWK DQ LQFUHDVH LQ FKURQLF FRUSRUDO LQÀDPPDWLRQ VFRUH
corporal atrophy score and corporal intestinal metaplasia score 
were separately compared between ARS and omeprazole groups 
in H. pylori-negative and positive patients. The two groups were 
similar for all comparisons.
Omeprazole versus ranitidine
Omeprazole-treated patients were compared to ranitidine-treated 
patients in two RCTs (Dent 1994, Hallerback 1994).26,27 Of 343 
patients treated with omeprazole (20 mg/day), 1 developed simple 
(diffuse) hyperplasia and 7 developed linear and/or micronodular 
hyperplasia of the ECL cells whereas in 168 ranitidine-treated pa-
tients, 1 developed simple (diffuse) hyperplasia and 1 developed 
linear and/or micronodular hyperplasia of the ECL cells [P = 0.49 
for simple diffuse hyperplasia (Analysis 2) and P = 0.31 for linear 
and/or micronodular hyperplasia (Analysis 3), respectively]. 
Discussion
PPIs are widely used in patients with GERD and proven to be su-
perior to other anti-secretory agents in terms of healing and symp-
tom relief. However, when used for maintenance therapy their 
long-term safety is of concern. This study has addressed the ques-
tion of long-term PPIs safety by comparing the incidence of gas-
tric malignant and premalignant lesions in patients on long-term 
PPI with those who did not receive this treatment. Three main 
FKDUDFWHULVWLFVRIJDVWULWLVLHFKURQLFLQÀDPPDWLRQDWURSK\DQG
intestinal metaplasia) and ECL cell hyperplasia were scored at 
EDVHOLQHDQG¿QDOELRSVLHV2XUUHVXOWVKDYHVKRZQWKDWWKHQXP-
EHURISDWLHQWVZLWKZRUVHQLQJFKURQLFLQÀDPPDWLRQDWURSK\DQG
LQWHVWLQDOPHWDSODVLDVFRUHVIURPEDVHOLQHWR¿QDOELRSVLHVZHUH
typically less than the number of patients with improved or un-
YDU\LQJVFRUHV1RVLJQL¿FDQWGLIIHUHQFHFRXOGEHIRXQGEHWZHHQ
the PPI maintenance group and controls.
ECL cell morphology has been investigated in the majority of 
included studies. While ECL cell morphologic ratings have seven 
scales that range from normal to invasive carcinoid tumor, none 
Analysis 1.7KHQXPEHURISDWLHQWVZLWKLQFUHDVH:RUVHQLQJLQ&RUSRUDO&KURQLF,QÀDPPDWLRQ
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of the included studies reported any changes in ECL morphology 
above scale 3 (i.e., micronodular hyperplasia). Nevertheless, in a 
ten year study by Lamberts et al. on a total of 61 patients treated 
with 40 mg/day omeprazole, there was a relative worsening of 
gastritis and gland atrophy (but no dysplasia or neoplasia) in the 
presence of H. pylori infection.63
,WLVZHOOGRFXPHQWHGWKDW33,VDUHPRUHHI¿FDFLRXVLQSUHYHQW-
ing GERD symptom relapse compared to H2RAs such as raniti-
dine. Hereby our study further supports PPI use in GERD main-
tenance therapy by showing that omeprazole and ranitidine have 
VLPLODUVDIHW\SUR¿OHV
,Q VXPPDU\ RXU ¿QGLQJV VXJJHVW WKDW ORQJWHUP33,PDLQWH-
nance therapy in patients who suffer from GERD is not associated 
with an increased risk of developing ECL cell hyperplasia, gastric 
FKURQLF LQÀDPPDWLRQ DWURSK\ DQG LQWHVWLQDOPHWDSODVLD7KHVH
medications can be safely used for at least a period of 12 months.
Of the six included studies four had an unclear or high risk 
of bias (Lundell 1999; Dent 1994; Hallerback 1994; Gough 
1996)14,26–28 and two had low risk of bias (Johnson 2001; Vakil 
2001).29,30 When only studies with low risk of bias were included 
in the meta-analysis, no changes in the results were observed with 
the exception of one case where patients were grouped according 
to PPI dosage. The result of the analysis on studies with low risk 
RIELDVVKRZHGVLJQL¿FDQWO\ LQFUHDVHG(&/FHOO VFRUHVZLWK
mg and 40 mg of esomeprazole (but not with 10 mg) compared to 
placebo, while such an effect could not be observed when all the 
relevant studies were included in the meta-analysis.
Potential risk of bias
Beyond the usual potential risk of publication bias in develop-
ing the reviews, there were two additional reasons for increasing 
probability of this type of bias in our review, stated as follows. 
7KHUHZDVLQVXI¿FLHQWGDWDLQWKHSXEOLVKHGSDSHUVRIVRPHWUL-
als.31,32 We requested additional information from the contact au-
thors by mail. Unfortunately they could not help us; therefore we 
excluded these trials from the meta-analysis.
Considering the published protocol of the review we excluded 
some potentially useful data from other prospective non-random-
ized trials such as large cohorts that had a long duration of follow-
up which might be more valuable than RCTs in the assessment of 
premalignant lesions. 
&RPSDULQJWKHUHVXOWVZLWKWKHUHVXOWVRIRWKHUVWXGLHV
$VPHQWLRQHGDERYHZKHQFKURQLFLQÀDPPDWLRQDWURSK\DQG
intestinal metaplasia scores were investigated we found no sig-
QL¿FDQWGLIIHUHQFHEHWZHHQ33,PDLQWHQDQFHJURXSVDQGFRQWUROV
This was consistent with two clinical trials where patients had 
YHU\ IHZRU LQVLJQL¿FDQWFKDQJHV LQ WKH WKUHHFKDUDFWHULVWLFVRI
gastritis from baseline to the end of the study.49,67
Atrophic gastritis can potentially progress to gastric cancer. 
Therefore, the effect of H. pylori infection on the development of 
atrophic gastritis in patients on long-term PPI is of major concern. 
Lundell14 has conducted the only RCT that investigated such an ef-
fect. This was a three-year long study with two intervention arms, 
a PPI maintenance group and an ARS group. This study showed 
no difference in progression of atrophy between treatment arms 
in the H. pylori-positive group. This contrasted a non-randomized 
¿YH\HDUVWXG\.XLSHU13 where atrophic gastritis was more 
commonly seen in H. pylori-positive patients on PPI maintenance 
therapy compared to H. pylori-positive patients who underwent 
$56%RWKVWXGLHVKRZHYHUVKRZHGQRVLJQL¿FDQWGLIIHUHQFHLQ
development of gastric atrophy between treatment arms, when 
H. pylori-negative patients were evaluated. Though interesting, 
.XLSHUV¶¿QGLQJVVKRXOGEHWUHDWHGZLWKFDXWLRQ)LUVWO\WKHWULDO
was non-randomized; secondly, omeprazole-treated patients were 
VLJQL¿FDQWO\ROGHUWKDQSDWLHQWVLQWKHDQWLUHÀX[JURXS7KLVGLI-
ference was more prominent in H. pylori-positive patients. Third-
ly, the omeprazole and ARS groups were chosen from different 
countries. Despite the initial contrast between these studies, when 
Lundell’s data were re-grouped into no/mild versus moderate/se-
Analysis 2. Increase in the number of reported simple (diffuse) hyperplasia in the ECL cells after treatment.
Analysis 3. Increase in the number of reported Focal (Linear and/or micronodular) hyperplasia in the ECL cells after treatment.
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vere atrophy, the results would be consistent with Kuipers’ study 
(i.e. the number of H. pylori-positive patients on PPI therapy who 
GHYHORSHGPRGHUDWHVHYHUHDWURSK\ZDVVLJQL¿FDQWO\KLJKHUWKDQ
H. pylori-positive patients who underwent ARS).747KHVH¿QGLQJ
suggested that eradication of H. pylori could well prevent the de-
velopment of atrophy in patients on long-term PPI therapy.
Conclusion  
Maintenance PPIs have not been shown to be associated with 
increased gastric atrophic changes or ECL hyperplasia for at least 
three years in RCTs. Clinically unimportant ECL cell hyperplasia 
may be associated with higher esomeprazole doses (more than 20 
mg/day), but whether this is progressive and whether it is a class-
effect cannot be judged according to current knowledge. Possibly, 
the presence of H. pylori may be associated with increased in-
ÀDPPDWRU\FKDQJHVLQFKURQLF33,XVHUVEXWQRWZLWKDWURSKLFRU
hyperplastic changes.
Considering the moderate risk of bias in the majority of included 
studies, further long-term trials with larger sample sizes, longer 
duration and better quality are necessary, particularly to address 
the issue of concomitant H. pylori effect.
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Appendix 1. Characteristics of the excluded studies.
Excluded study Reason for exclusion
Arroyo 199737 The control group does not meet the eligibility criteria.
Athmann 199838 Inappropriate study design (uncontrolled clinical trial).
Bardhan 200139 Inappropriate study design (uncontrolled clinical trial).
Berstad 199740 Inappropriate study design (uncontrolled clinical trial).
Brunner 198941 Inappropriate study design (uncontrolled clinical trial).
Dekker 199942 Inappropriate study design (uncontrolled clinical trial), the abstract form of the Geboes 2001  study.
Diebold 199843 Inappropriate study design (case control study).
Driman 199644 Inappropriate study design (case control), the endpoints of the review was not assessed.
Eissele 199345 Inappropriate study design (uncontrolled clinical trial).
Eissele 199746 Inappropriate study design (uncontrolled clinical trial). Extension of the previous study (Eissele 1993).
Festen 199947 The duration of treatment was shorter than 6 months, there was no pathologic assessment.
Gardner 199933 Only the abstract of the paper was available.
Geboes 200148 Inappropriate study design (uncontrolled clinical trial).
Genta 199949 Only the abstract of the paper was available.
Havelund 198850 RCT with short duration of treatment (up to 12 weeks), the end points of our study were also not assessed.
Havu 199851 Inappropriate study design (uncontrolled clinical trial).
Hendel 200052 Only the abstract of the paper was available.
Hui 199153 RCT with short duration of treatment (up to 4 weeks).
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Meining 198831 7KHUHZDVLQVXI¿FLHQWGDWDLQWKHSXEOLVKHGSDSHU:HUHTXHVWHGDGGLWLRQDOLQIRUPDWLRQIURPWKHFRQWDFWDXWKRUE\PDLOunfortunately he could not help us.
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Nishi 200532 7KHUHZDVLQVXI¿FLHQWGDWDLQWKHSXEOLVKHGSDSHU:HDVNHGPRUHLQIRUPDWLRQIURPWKHFRQWDFWDXWKRUE\PDLOunfortunately he could not help us.
Richter 200335 Only the abstract of the paper was available.
Sandmark 198867 RCT with short duration of treatment (up to 12 weeks), the end points of our study were alsonot assessed.
Schenk 199968 Inappropriate study design (uncontrolled clinical trial).
Solcia 199269 Inappropriate study design (uncontrolled clinical trial).
Stolte 199870 Controlled clinical trial, control group was not eligible; both groups received PPI.
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